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ABSTRACT 
International Conference on Harmonization (ICH) has formulated different guideline regarding the control of impurities. In this review,  the 
impurity sources, classification, isolation, detection and characterization methods are described. The some impurities are unavoidable and will 
be present in trace amounts hence ICH guidelines frame the different policies and establish the specification limits, isolation and 
characterization is necessary for evaluation and control of impurities. The other regulatory bodies and drug development authorities look up to 
these guidelines for launching a quality drug into the market. Validation of analytical process for impurity identification i s performed to 
establish the impurity profile of any drug substance. Hence the major focus of this review article is on isolation and characterization of 
impurities using various technics, sources and classifications, establishment of impurity profile and analytical approaches to establish its 
profile. We also could apply the QbD to providing statistical documentary evidences. 
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Introduction: 
The active pharmaceutical ingredients (APIs) manufacturing 
industries are the base of all kind of pharmaceutical 
manufacturing industries to provide the sufficient or 
specified quality of APIs. The major challenge for bulk drug 
industries is to produce the final drug of required quality 
and purity, economically. That’s almost impossible to obtain 
absolutely pure materials, as impurities get incorporated 
into them either during manufacture, purification or during 
storage. So, to identify the nature of all the related 
substances or impurities we have to develop method for 
Isolation, Separation, characterization and quantification of 
impurities in drug compounds (Gabhe, et al., 2011). It is a 
very critical task in pharmaceutical product development for 
quality and safety. Chromatographic isolation and 
separation of impurities can be a challenging process for the 
analytical laboratory.  Generally ssuitable analytical 
instrumentation and multiple chromatographic methods are 
required (Prafulla Kumar Sahu, et al. 2015). Conventional 
preparative HPLC approaches result in large (often aqueous) 
fraction volumes, instability of the collected fractions.  
Supercritical Fluid Chromatography (SFC)  helpfull to 
eliminate these problems.  In comparison with reversed-
phase and normal phase HPLC, SFC offers rapid method 
development and high efficiency of preparative separations 
through increased loading capacity, faster linear solvent 
velocity, and drastically reduced solvent removal effort. Also 
this facilitate stepwise protocols that would be impractical 
using other chromatography (Ashraf-Khorassani et al., 
2005). Various analytical methodologies were employed for 
the separation and determination of related components in 
pharmaceuticals. Impurity profile describes the identified 
and unidentified impurities present in a new drug substance 
and drug products. Impurity profiling is the common name 
of a group of analytical activities, the aim of which is the 
detection, identification/structure elucidation and 
quantitative determination of organic and inorganic 
impurities as well as residual solvents in bulk drug 
substances and pharmaceutical formulations (ICH Agency, 
2006). The  evolution of chemical knowledge and the 
emergence of increasingly sensitive and selective analytical 
methods have been continuously stimulating the interest in 
the determination of drug purity and the impurities 
themselves in both, natural and synthetic products. This is in 
line with the policy of the pharmaceutical industry, which 
has always demanded that the API should be as pure as 
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possible to achieve efficacy and safety of drug. Two main 
factors determining the safety of drug therapy are: 
1. Pharmacological and toxicological profile of drug 
substances: the relationship of beneficial and adverse effects 
of the drug. 
2. The impact of impurity present in drug substance: 
Analytical chemist play important role in monitoring and 
controlling impurities in drug substances. 
In pharma industry the rapid isolation separation, detection, 
identification, elucidation, and characterization of synthetic 
or process impurities or degradants is an intense and 
comprehensive undertaking. Regulatory agencies including 
the USFDA and ICH mandate dose dependent thresholds for 
Reporting, Identification, and Qualification of impurities. For 
example, in the development of a formulated drug substance, 
the FDA requires that all impurities introduced in the 
proposed process above 0.1 by area percent need to be 
isolated and structurally characterized (the requirement can 
be even lower for drugs with larger doses). Impurities from 
synthesis, manufacture, or storage are all of interest. 
Furthermore, in order to develop a robust drug product, 
degradation products must be characterized with the intent 
of minimizing their presence. Thus preserving the shelf life 
of the formulated drug product (Agency, 2006; ICH, 2006a, 
2006b; Gabhe, Desai and Patel, 2011). 
Glossary 
Intermediate: The compounds formed in the process of 
synthesis for the desired product are called intermediates or 
reaction intermediates. They are defined as products that 
have undergone a partial processing and are used as raw 
material in a successive productive step.  
Penultimate intermediate: As the name suggests, this is 
the compound found in the synthesis chain before the 
production of the desired compound. Sometimes confusion 
arises when the desired material is a salt of a free base or 
acid. In our opinion, it is inappropriate to label the free base 
or acid as the penultimate intermediate if the drug substance 
is a salt. 
By-product: The unintentional compounds that arise during 
the reaction are commonly called by-products. Not all by-
products can be quantified easily; hence, they present a 
thorny problem to the analytical chemist. A by-product can 
be useful and marketable or it can be considered waste. 
Transformation product: This relates to an expected and 
non-expected product that may be formed in the reaction. 
Transformation products are very similar to by-products, 
except the term tends to connote that more is known about 
the reaction products than transformation products. 
Interaction product: This term is slightly more 
comprehensive and more difficult to evaluate than by-
products and transformation products in that it considers 
interactions occurring among various chemicals involved in 
reaction.  
Related product: As mentioned, impurity is a word that is 
not well liked. So a related product actually is similar to an 
impurity, but active pharmaceuticals use the term related 
products instead, thus playing down the negativity 
frequently attached to the term impurity. These products 
can have similar chemical structure and might have 
standardized biological activity; however, this by itself does 
not provide any guarantee of effect.  
Degradation product: The compounds produced due to 
decomposition of the material of interest or active 
ingredients often are referred to as degradation products 
(Singh. et. al,.  2017). 
Foreign substance: This is the material that may be present 
due to contamination or adulteration, not as outcomes of 
synthesis.  
Toxic impurity: Toxic impurities might affect the biological 
activity, even at very low concentrations. They require 
identification by qualitative or quantitative means. 
Concomitant component: Bulk pharmaceutical chemicals 
may contain concomitant components, which are geometric 
and optical isomers and antibiotics that are mixtures.  
Ordinary impurity: An impurity having enough potency to 
have biological activity even at trace level is called an 
ordinary impurity.  
Organic volatile impurity: A solvent that may remain in the 
drug substance should be considered as an organic volatile 
impurity (OVI). 
Threshold: A boundary beyond which radically different 
state of affaire exists.  
Identified Impurity: An impurity for which a structural 
characterisation has been achieved.  
Unidentified Degradation Product: A degradation product 
for which a structural characterisation has not been 
achieved and that is defined solely by qualitative analytical 
properties (e.g., chromatographic retention time). 
Unspecified Degradation Product: A degradation product 
that is limited by a general acceptance criterion, but not 
individually listed with its own specific acceptance criterion, 
in the new drug product specification. 
Penultimate Intermediate: It is the last compound in the 
synthesis chain prior to the production of the final desired 
(Venkatesan and Valliappan, et. al 2014). 
Process impurity: An impurity generated during drug 
substance manufacturing. Process related impurities may 
include starting materials, byproducts, intermediates, 
reagents, ligands, and catalyst.  
Identification Threshold: A limit above (>) which an 
impurity should be identified. 
Qualification: The process of acquiring and evaluating data 
that establishes the biological safety of an individual 
impurity or a given impurity profile at the level(s) specified. 
Qualification Threshold: A limit above (>) which an 
impurity should be qualified. 
Reporting Threshold: A limit above (>) which an impurity 
should be reported. Reporting threshold is the same as 
reporting level in Q2B  (ICH Agency, 2006).  
Regulatory guidelines on impurity: 
 The United States Food and Drug Administration (FDA) 
inscribe International Conference on Harmonization 
guidance of Technical Requirements for Registration of 
Pharmaceuticals for Human Use. The food and drug 
administration assigned responsibility to ensure the safety 
and efficacy of drugs. The various regulatory agencies frame 
the guidelines regarding impurities are as follows: 
1.   ICH guidelines “Stability Testing of New Drug Substances 
and Products”- Q1A. 
2.   ICH Guidelines “Impurities in New Drug Substances”- 
Q3A. 
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3.   ICH Guidelines “Impurities in New Drug Products”- Q3B. 
4.   ICH Guidelines “Impurities: Guidelines for Residual 
Solvents”- Q3C. 
5.   US-FDA Guidelines “NDAs- Impurities in New Drug 
Substances”. 
6.   US-FDA Guidelines “ANDAs- Impurities in New Drug 
Substances”. 
7.   Australian Regulatory Guideline for Prescription of 
Medicines, Therapeutic Governance 
Authority (TGA), Australia (Venkatesan and Valliappan, 
2014).
 
 
Figure 1: Classification of Impurities: 
 
According ICH guidelines Q3A, Q3B and Q3C and USP 
Impurities classification  
A. According ICH guidelines Q3A, Q3B and Q3C                                  
Organic impurities 
These can be formed during the manufacturing process or 
during storage of new drug substances. They can be 
identified/unidentified, volatile/non-volatile. This includes 
starting materials, intermediates, by-products, DPs, reagents, 
ligands and catalysts. 
Inorganic impurities 
These can arise during manufacturing process; normally they 
are known and identified. This includes: reagents, ligands, 
catalysts, heavy metals, other residual metals, inorganic salts 
and other materials like filter aids, charcoal. Examples, 
Cadmium, manganese, sodium etc. 
Residual solvents 
These are generally inorganic/organic liquids that are used 
during synthesis of drug substances as a vehicle for 
preparation of solution or suspension. Appropriate control of 
residual solvent is necessary since they have known toxicity. 
ICH Q3C guideline provides the limits of residual solvent 
based on existing safety and toxicity data. These were 
classified in three categories: 
Class 1 (The most toxic and/or environmentally 
hazardous):  
These are highly toxic in nature and are limited to 28 ppm, 
for environmentally hazardous chemical   like 
trichloroethane   the   limit   of   1500   ppm      is   applied.   
During   manufacturing   of pharmaceuticals Class 1 solvents 
should be avoided. But if their presence is unavoidable, the 
definite concentration limit is applied, regardless of the 
actual patient intake dose. Examples, Benzene, carbon 
tetrachloride, 1, 1, dichloromethane,  
 
Class 2 (Considered a lesser risk): 
 These should be limited in their usage. Two different 
1approaches were described in guideline for setting limits of 
class 2 solvents. The first approach is used when PDE 
(permitted daily dose) cannot be estimated; concentration 
limits are calculated on the basis of daily intake of theoretical 
product mass of 10g. The second approach is used when 
dose is known; the PDE and/or dose value can be used to 
determine the permissible concentration. Examples, 
Acetonitrile, Chloroform, 1, 2,-Dioxane, Pyridine, Toluene. 
Class 3 (The lowest risk category): 
 These have low toxic potential and are limited to 5000 ppm 
(0.5% w/w). Examples, Acetic acid, acetone, ethanol, butanol, 
isopropyl alcohol. 
Sources of Impurities (Venkata et.al., 2016). 
Others-Enantiomeric impurities: 
In optically active drug there could be an isomer with 
enantiomeric impurities. Many drugs are chiral and are often 
supplied as mixtures of enantiomers rather than single 
enantiomers (Prafulla Kumar Sahu, 2015). 
B. According USP Impurities classified as 
a. Ordinary impurities:  Ordinary impurities are found in 
bulk pharmaceutical chemicals that are innocuous by virtue 
of having no significance on the biological activity of the 
drug substance. These impurities may arise out of the 
synthesis, preparation or degradation of the chemical. 
b. Organic volatile impurities: Organic volatile chemicals 
are produced in the manufacture of drug substances or 
excipients or in the preparation of drug products; they are 
volatile in nature and by themselves get removed out at time 
of storage or processing (Bari et al., 2007, ) (Saibaba, Kumar 
and Ramu, 2016).  
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Sources of impurities: 
Synthesis Related Impurities: During synthetic process, 
impurities in new drug substance or new chemical entity 
(NCE) mainly originate from raw materials, intermediates, by 
products and solvents. Generally in pharmaceutical 
synthesis, the purity of final intermediate is controlled by 
performing regulatory purity/impurity testing. Example, p-
Chlorophenyl glutaric acid is a synthesis impurity of 
Baclofen. 
Formulation Related Impurities: The  excipients  used  to  
formulate  drug  products,  can  generate  potential  
impurities.  In addition during the process of formulation the 
drug is subjected to variety of conditions like heat, shear etc, 
that can contribute undesirable reactions and forms 
Degradation products. Hydrolysis or solvolysis generally 
takes place in solutions and suspensions that leads to 
degradation. Vortex mixing are sometimes used during 
process of formulation that is considered high risk 
operations which can cause impurity formation. Example, 1-
(2, 6-Dichlorophenyl) Indoline is formulation impurity of 
Diclofenac. 
Degradation Related Impurities: Number of impurities can 
be generated due to degradation of API and/or other 
interactions on storage.  Therefore,  it  is  important  to  
conduct  stability studies  in  order  to  predict, evaluate and 
ensure drug product self-life. Stability studies include 
evaluation of API stability, pre-formulation studies in order 
to evaluate compatibility of API with the excipients to 
evaluate its stability in the formulation matrix, accelerated 
stability testing of the drug product, kinetic studies and 
determination of expiration date, stability studies of drug 
products in market. The stability studies were conducted 
under various exaggerated conditions of humidity, light and 
temperature that helps to determine which type of 
impurities can be generated by degradation reactions. 
Example, Disulfonamide is a degradation Impurity of 
Hydrochlorothiazide. 
Stereochemistry-related impurities: Stereochemistry 
related compounds are those compounds that have similar 
chemical structure but different spatial orientation, these 
compounds can be considered as impurities in the API’s. 
Chiral molecules are frequently called enantiomers. The 
single enantiomeric form of chiral drug is now considered as 
an improved chemical entity that may offer a better 
pharmacological profile and an increased therapeutic index. 
Example, R- omeprazole is an impurity of esomeprazole. 
 Reagent, Ligands and Catalysts: These impurities are 
pretty rare. Proper care during the manufacturing process 
avoids the chance of these kinds of impurities. 
 Heavy Metals: Water is essential during manufacturing 
process and it is the main source of heavy metals, like Ar, Cd, 
Cr, Na, Mg, Mn, etc. These can be avoided by the use of 
demineralization plant, reverse osmosis technique that 
produces mineral free water (Ayre et al., 2011). 
Other Materials (Filter Aids, Charcoal): The filters or 
filtering aids are routinely used in the bulk drugs 
manufacturing plants and sometimes activated carbon is also 
used which acts as a source of impurity. For that reason 
regular monitoring of fibres and black particles are needed 
to avoid the contamination (Venkata Pavan Kumar G. 
Prameela Rani, Pooja and Anil Kumar, 2016). 
Crystallization-Related Impurities: Polymorphism is the 
term used to denote crystal systems where a substance can 
exist in different crystal packing arrangements, all of which 
have the same elemental composition. It is also possible to 
have crystal systems where the substance exists in different 
crystal packing arrangements, each of which has a different 
elemental composition; this phenomenon is known as 
solvatomorphism. Based on the realization that the nature of 
the structure adopted by a given compound upon 
crystallization could exert a profound effect on the solid-
state properties of that system, the pharmaceutical industry 
is required by regulatory authorities to take a strong interest 
in polymorphism and solvatomorphism. The nature of the 
crystal structure of a given material can influence the 
following properties given in Table No.1. (Bari et al., 2007)
 
Table 1: List of properties that influences the crystal structure of a impurities(Bari et al., 2015). 
Sr. No. Name of Properties Sr. No. Name of Properties 
1 Conductivity 11 Dissolution rate 
2 Diffusivity 12 Density 
3 Solubility 13 Latent heat of fusion   
4 Hygroscopicity 14 Heat of solution 
5 Crystal hardness 15 Rates of reactions     
6 Crystal shape and colour 16 Phase diagrams     
7 Volume 17 Refractive index 
8 Crystal hardness 18 Heat capacity     
9 Enthalpy of transitions     19 Melting or sublimation properties 
10 Surface tension 20 Polymorphism 
 
Factors affecting on formulation related 
impurities: 
A. Environment related: 
a. Exposed to adverse temperature: Substance which are 
labile to heat or in tropical temperature lead to degradation 
of active constitute and formation of impurity occurs. E.g. 
Vitamins are heat sensitive and its degradation lead to loss 
in potency. 
b. Exposed to light: Photosensitive material when exposed 
to light / UV light undergo degradation which forms 
impurity. 
c. Humidity: It can be detrimental to bulk powder and 
formulation containing solid dosage form. 
B. Formation of impurities on ageing: 
a. Mutual interaction: Interaction between ingredients 
involved in formulation lead to mutual interaction which 
causes impurity formation. 
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C. Functional Group Related Impurities 
a. Ester hydrolysis: Drugs like aspirin, benzocaine, 
cefoxime, cocaine, ethyl paraben undergo ester hydrolysis. 
b. Hydrolysis: Commonly drugs like benzyl penicillin, 
barbital, chloramphenicol undergo hydrolysis. 
c. Oxidative degradation: Drugs like hydrocortisone, 
methotrexate, heterocyclic aromatic ring, nitroso/nitrile 
derivative. 
d. Photolytic cleavage: Product exposed to light while 
manufacturing or storage in hospital pending use or by 
consumer pending use. 
e. Decarboxylation: some dissolved carboxylic acid such as 
P-Amino salicylic acid Loose CO2 when it heated(Pawale, et. 
al., 2012). 
D. Packaging material Related Impurities: Impurities 
formed from packaging material like closures and 
containers. For most drugs, water, metals, peroxides derived 
from the packaging material can lead to formation or 
introduction of impurities. Various impurities such as 
polypropylene, zinc stearate (stabilizer in PVC), styrene, and 
diethylhexylpthalate (DEHP) etc. can leach in from rubber 
stopper and plastic material; whereas oxides like NO2, SiO2, 
CaO and MgO can be released from glassy surfaces (Singh. et. 
al,.  2017).  
 
Isolation: 
Isolation   and   characterization   of impurity is depends 
upon the nature of the impurity that means structure of 
impurity, its physicochemical properties and availability.  It 
is often necessary to isolate impurities because the 
instrumental methods that were mentioned earlier for 
directly characterizing impurities without isolating them are 
not available or when the authentic material is needed for 
further confirmation of the structure or its toxicity. Isolation 
and removal of the compound of interest from the other 
compounds present in a mixture. Further purification is 
achieved based on the compounds intended use. The first 
two sections, solid-phase extraction and liquid-liquid 
extraction deal with liquid samples. The sections on 
supercritical fluid extraction and accelerated solvent 
extraction focus mainly on solid samples while the 
centrifugation and filtration sections handle suspensions. 
Isolation methods include both chromatographic and non-
chromatographic methods. Simple methods should be tried 
first, as they can lead to considerable savings in time and can 
produce a larger quantity of materials with greater ease 
(Singh et al., 2017). For isolation of a given compound from a 
complex mixture, the chromatographic methods utilized for 
separation of impurities in analytical determinations are the 
methods of first choice that are suitably modified for the 
purpose of isolation of impurities where an appropriate 
fraction is collected. For isolation of impurity Following   
methods   are   commonly   used   for   the isolation as below 
(figure no.2). 
 
 
Figure 2: Isolation of impurities (Alsante et al., 2001) 
Solid-phase extraction methods: The conventional process 
of solid-phase extraction involves passing a liquid sample 
over a solid surface in order to separate target analytes from 
the sample matrix. The attractive interactions of the analyte 
with the solid surface must be greater than the attractive 
interactions of the analyte with the sample matrix in order 
for retention and extraction to occur. The technique is based 
on the same principles as chromatographic separations 
(partitioning, adsorption, or ion exchange).  
Liquid-liquid extraction methods (LLE): This simply 
entails extraction of one liquid with another generally one of 
those liquid is aqueous and other is organic. The primary 
requirement is that these liquids to be immiscible.  This 
procedure is very useful when the liquid into which the 
material of interest is being extracted is easy to volatilize, 
thus permitting concentration of the material. Hence the 
choice of solvents must be made with that consideration in 
mind. Liquid–liquid   extraction  is  a  very  good  sample  
clean up  technique  for nonpolar  or  moderately   polar  
analytes  that  can  be  deionized  in  aqueous solution  by  
simple  pH  adjustment.  From  a  practical   perspective,  the  
best recoveries  are  obtained   when  an  excess  of  organic  
solvent  (3-  to  10-fold excess) or  multiple-step  extractions 
are  used.  Multiple step extractions have recently fallen into 
disfavour for routine use because they are time-consuming 
and labour-intensive. In this type of extraction process, a 
solute is distributed between two immiscible solvents. The 
extraction is controlled by distribution or partition co-
efficient which defines the ratio of concentration of the 
solute in two solvents a and b. 
                                                        Kd   =   Ca / Cb 
Kd   is the distribution co-efficient or partition coefficient. 
The distribution co-efficient related to a single species and 
does not include possible products of side reactions. 
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Liquid-solid extraction 
To simplest form, a solvent is selected that would dissolve 
the impurity of interest but not the solid matrix. If 
compound contains more than one impurity means, in that 
case desirable to use an organic solvent for extraction 
because of its unique properties. It is generally easier to 
volatilize the organic solvent at low temperatures in order to 
concentrate the impurity.  
Table 2: List of solvents for Liquid-Solid extraction. 
Solvents Boiling Point Dielectric constant 
n-Hexane 190 1.9 
Cyclohexane 81 2 
Methanol 65 32.7 
Dimethyl formamide 153 36.7 
Acetonitrile 82 37.5 
Water 100 80 
 
Supercritical fluid extraction: It can be argued that the 
first supercritical fluid extractions (SFE) were performed in 
1879 when Hannay and Hogarth investigated the solvating 
capabilities of ethanol. However, it took roughly 100 years 
ago supercritical fluids made any significant impact on 
industrial processes. The removal of caffeine from coffee 
beans was reported in the 1970s and led to a large increase 
in the number of published articles focusing on large-scale 
extractions using supercritical carbon dioxide. Supercritical 
fluid extraction (SFE), with Aid of carbon dioxide as the 
solvent, was tested for its ability to remove common reactive 
impurities from several pharmaceutical such as extraction of 
the small molecule impurities, formic acid and formaldehyde 
etc. The development of commercial supercritical fluid 
chromatographs and extraction systems escorted a slew of 
publications about analytical scale work in the 1980s 
(Deshpande et al., 2012). In general, the use of supercritical 
fluids for extraction was touted as having several advantages 
over traditional extraction techniques such as LLE. These 
included lower solvent cost, better selectivity through 
pressure and temperature modification, and better solvating 
power because of fluid properties. A complete 
understanding of SFE and its relation to other extraction 
methods cannot be made without some knowledge of the 
basic properties of supercritical fluids and the basic 
principles of analytical SFE instrumentation. The purpose of 
this section is to give an introduction to the use of 
supercritical fluids in analytical-scale extractions while 
focusing on the application of SFE to pharmaceutical analysis 
(Ashraf-Khorassani et al., 2005). 
Table 3: List of solvents for SFE 
Solvent Pressure(ATM) Temperature 
n-Pentane 33.3 196.6 
Carbondioxide 72.9   
Ammonia 111.3 132.3 
 
Column Chromatography: This technique is commonly 
used for the separation of pharmaceutical compounds in 
preparative chemistry. The separation of quantities ranging 
from micrograms to kilograms,  which  depends  on  the  size  
of  the  column. Detection of the eluent is generally 
performed by UV- spectrophotometry, either continuously 
by using a flow cell or periodically by monitoring the 
collected fractions from a given sample that alerts the 
emergence of UV- active components.  Commonly silica gel 
or alumina is used in classic adsorption chromatography.  
Ion exchange resins to chemically modified polydextran gels 
used primarily for the analysis of biological samples. For 
liquid-liquid partition chromatography columns, inert 
carrier such as celite or kieselguhr is impregnated with an 
aqueous buffer or another polar solvent such as dimethyl 
formamide or dimethyl sulfoxide and elution is carried out 
with non-polar solvents. 
Thin Layer Chromatography: It is a valuable technique for 
isolation and purification of compounds. All the modes of 
chromatography including adsorption, partition, ion 
exchange and gel filtration can be utilized.  In addition 
choosing a sorbent and an eluent for performing TLC it is 
necessary to select a suitable method for applying a sample 
to the plate. Silica gel plates with or without fluorescent 
indicator are frequently used for most application. Detection 
is frequently performed by UV eg. 366nm or Iodine vapours 
can help to detect most of the organic substance. To elute the 
material from the plates, the simplest method is scraping the 
sorbent containing the material of interest and it is extracted 
with a suitable solvent, followed by filtration or 
centrifugation. The solvent is removed to collect the desired 
substance. If aluminium plates are used means cut the 
sample and eluted (Singh. et. al,.  2017). 
Gas Chromatography: It is very useful for isolation and 
characterization of volatile components or those 
components that can be made volatile by derivatization 
technique and the detector used should be non-destructive. 
Now GC is more appropriate to be used in combination with 
mass spectrometry (GC/MS) for characterization of 
impurities (Singh. et. al,.  2017). [14] 
Process Chemistry 
Process Chemists are responsible for developing the 
synthetic route for development candidates. They are 
expected to collaborate with the other groups below to 
facilitate the identification and characterization of impurities 
or to refine their synthetic route design to eliminate or 
minimize the presence of these impurities. Critical factors 
affecting the quality of bulk drugs are; 
1. Crystallization 
2. Washing the wet cake 
3. Drying 
4. Appropriate packaging 
1. Crystallization: The size of crystals sometimes 
determines the quality, especially the stability, of bulk drugs. 
Large-size crystals can entrap a minute amount of chemicals 
from the mother liquor, which ultimately causes the 
degradation of the drug. Thus, the manufacturers of bulk 
drugs should take care to produce finer crystals while 
isolating the products. 
2. Washing the wet cake Washing the wet cake or powder 
in the centrifuge should be thorough to re-move unwanted 
chemicals including residual sol-vents. 
3. Drying- Use of a vacuum dryer or a fluid-bed dryer is 
always preferable to a tray dryer in the pharmaceutical bulk 
drug industry. The high thermal efficiencies, reduction of 
drying time, and more uniform drying are helpful in drying 
sensitive drug substances. However, if a tray dryer is used 
then initial airflow at ambient conditions should be 
considered before exposing the materials to a relatively 
higher fixed temperature. 
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4. Appropriate packaging Light- sensitive pharmaceutical 
products need light protective packaging. An accelerated 
stability testing conducted using marketed ampoules of 
ergometrine wrapped with either black carbon paper or 
aluminium foil produced negligible degradation against 
direct sunlight. Similar use of opaque containers for 
ciprofloxacin eye drop preparation can protect the active 
ingredient from photo degradation to some extent compared 
with transparent containers (Saibaba et.al., 2016). 
Strategy for Method Development  
A. Method development strategy should have the following 
details. 
1. Physico chemical data 
2. Ionization constant 
3. Solubility 
4. Water absorption 
5. Distribution co-efficient 
6. Optical rotation 
7. Crystal form (Venkata et.al., 2016) 
B. Impurities can be analyzed by the following instruments: 
1. Ultra Violet Spectroscopy 
2. IR Spectroscopy 
3. NMR Spectroscopy 
4. Mass Spectrometry 
5. Gas Chromatography 
6. HPLC (Prafulla Kumar Sahu, 2015). 
Need to Identify Impurities: Impurities are generally 
assumed to be inferior to API because they might not have 
the same level of pharmacologic activity. However, they are 
not necessarily always inferior. From the standpoint of its 
usage, the drug substance is compromised in terms of purity 
even if it contains another material with superior 
pharmacologic or toxicologic properties. 
The control of low- level impurities is of great importance 
when a drug is taken in large quantities; for example, the use 
of methotrexate (10–20 g) to treat neoplasia. Penicillin and 
cephalosporin have been known  to  sustain  facile  cleavage  
of  the  β-lactam  bond  in  aqueous  solution.  This is 
particularly interesting since some studies on penicillin have 
shown that their lack of stability may influence possible 
reactions involved in penicillin allergy. Special attention 
should be paid to the detection of DNA in all finished 
biotechnology products because DNA can be incorporated in 
the human genome and become a potential oncogene. 
Analytical Research and Development: Pharmaceutical 
Development groups are ultimately responsible for the 
Chemistry, Manufacturing, and Controls sections of 
Investigational New Drug (IND) applications and New Drug 
Application (NDA) submissions. In general the various 
groups involved in this process from a synthetic chemistry 
and data collection and analysis. This group is basically 
responsible for the development of Drug Substance, Drug 
Product and specifications. This group will work combined 
with the process chemistry and structure characterization 
groups in concert to enable impurity profiling and chemical 
stability evaluation with degradant identification. The 
impurity profile method is developed by Analytical R&D and 
this method is used to help identify all impurities through 
each stage of the synthetic route and to help the 
characterization group decide which impurities require 
structure elucidation and characterization. In this group, a 
significant amount of time, technology, and knowledge is 
also invested in method development, tests of robustness, 
and validation (Vijayalakshmi R, 2012).  
Method for impurity detection and characterization 
After the impurity isolation and identification, it must be 
characterised following technics are generally utilised as 
shown figure-3. 
Highly sophisticated instrumentation, such as Ion 
Chromatography, Capillary Electrophoresis, HPLC, TLC and 
HPTLC, are inevitable tools in the detection of minor 
components (drugs, impurities, degradation products, 
metabolites) in various matrices. 
  
 
Figure 3: Methods of Impurities detection and Characterizations 
1. Infrared Spectroscopy (IR): IR-Spectroscopy Provides 
the information in the form of wave numbers which is 
indicate the presence of particular functional groups. 
Routinely used identification assay for various intermediates 
and final drug substances and also as quantitative technique 
for solution phase study. The IR traditional technique are 
used for characterization including identification and 
structural elucidation of molecules, solid state 
characterization such as polymorphism (Devid E.B. et. al., 
2002). 
2. Nuclear Magnetic Resonance (NMR): NMR provides 
information about specific bonding between peak area and 
number of nuclei responsible for peak. Most important 
application of NMR is identification and structure elucidation 
of molecules. Analysis of multicomponent mixture is possible 
using NMR technique. The ability of NMR- based diffusion 
coefficient determination to distinguish between monomeric 
and dimeric substances was validated using a standard 
mixture of authentic materials containing both monomers 
and dimers (Ingale et al., 2011).  
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3. Mass Spectroscopy (MS): Mass spectroscopy is a most 
relevant and sophisticated method for determining the 
molecular mass of the compound and its elemental 
composition. Mass spectroscopy is used to prove identity of 
two compound,  establish  the  structure  of  new  compound, 
give exact molecular mass, give molecular formula and most 
important for structure elucidation. Now a days mass 
spectroscopy connected with various hyphenated techniques 
like GC-MS, LC-MS,LCMS-MS HPLC- DAD-MS, HPLCDAD-
NMR-MS, Tandem Mass spectroscopy and capillary 
electrophoresis-Mass spectroscopy (Saibaba et.al., 2016). 
4. GC-MS: To identify different substances within a test 
sample  gas  chromatography-mass  spectrometry  (GC- MS) 
method used, that combines the features of gas- liquid 
chromatography and mass spectroscopy. In this method gas 
chromatography separate volatile and semi- volatile 
compounds with great resolution. Mass spectroscopy can 
provide detailed structural information on most compounds 
such that they can be exactly identified, but it cannot readily 
separate them. Sample vaporized by injection into a heated 
system, eluted through a column by inert gaseous mobile 
phase and detected. The sample is transported through the 
column by the flow of an inert, gaseous mobile phase, the 
carrier gas. Flow is regulated by the pressure regulators and 
gas metering valves. GC operates at atmospheric pressure 
and the MS ion source at 10-5 Torr.108 fold pressure 
difference. The carrier gas must be removed and GC peak 
components transferred to the MS ion source (Kulkarni, 
2018). 
5. LC-MS:   LC/MS   is   a   hyphenated   technique, combining 
the separation power of HPLC, with the detection power of 
mass spectrometry. LC/MS became really popular with the 
introduction of the thermospray interface and the particle 
beam interface. This is same as GC-MS but removal of liquid 
carrier from an HPLC eluent before samples are passed in to 
the MS source. For handle normal eluent flow rate 0.5-2.0ml 
min-1 which is not handled by MS pumping system moving 
belt inlet systems, jet separators and vacuum nebulizers are 
used (Saibaba, Kumar and Ramu, 2016). HPLC-DAD-MS  
(HPLC  coupled  with  a  diode  array  UV  detector  and  a  
mass spectrometer, and such other techniques are almost 
routinely used. In GC-MS of methamphetamine and in LC-MS 
of risperidone, and cetrizine tablets a number of other 
chromatographic and spectroscopic configurations are found 
to be perfectly suitable for initial characterization of the 
impurities. 
The single method most of time fails to provide the necessary 
selectivity then the coupling of chromatographic techniques 
such as HPLC-TLC and HPLC-CE, or coupling of 
chromatographic separations with information rich 
spectroscopic methods such as HPLC-MS or HPLC-NMR may 
need to be contemplated, but hopefully only as a 
development tool rather than a tool for routine QC use. Also 
the some Hyphenated techniques are crucially plays an 
important role in the segment of Impurity characterization. 
Within a short time these methods provides most relevant 
data to the chemist(Ingale et al., 2011; Saibaba, Kumar and 
Ramu, 2016). 
Hyphenated Methods: 
LC-MS-MS: The popularity of LC-MS-MS systems for complex 
mixture analysis of thermally labile and biologically relevant 
molecules viz. mosapride, is largely attributed to the soft 
nature of atmospheric pressure chemical ionization (APCI), 
and atmospheric pressure ionization (APPI). 
HPLC-DAD-MS: HPLC-DAD-MS  (HPLC  coupled  with  a  
diode  array  UV  detector  and  a  mass spectrometer, and 
such other techniques are almost routinely used. 
HPLC-DAD-NMR-MS: NMR has now been added to this 
combination to provide HPLC-DAD-NMR-MS capabilities in a 
commercial instrument (Ingale et al., 2011; Venkatesan and 
Valliappan, 2014).  
Control of organic impurities: Control of the organic 
impurities in new drug substances is based on the maximum 
daily dose and total daily intake (TDI) of the impurities. 
Table provides the ICH threshold for control of the organic 
impurities in new drug substances and new drug products 
(figure 4).  
 
 
Figure 4: Organic impurity threshold in new drug substances and drug products based on ICH. 
Depending on whether the maximum daily dose is higher or 
lower than 2g, organic impurities in a new drug substance at 
(or greater than) 0.05% or 0.1% requires identification. 
Based on the maximum daily dose, the identification 
thresholds for organic impurities in new drug products are 
divided into four groups to give more consideration to low 
dose drug products. For most of the new drug products, the 
maximum daily dose is between 10mg–2g/day. Therefore, 
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any impurities at 0.2% or greater would have to be 
identified (Agency, 2006; ICH, 2006b, 2006a).  
Implementation of quality by design approach 
Quality by Design (QbD) is “a systematic approach to 
development that begins with predefined objectives and 
emphasizes product and process understanding and process 
control, based on sound science and quality risk 
management” and has the aim of improving product quality 
and of increasing regulatory flexibility. Impurity level is a 
critical quality attribute for a drug substance or a drug 
product because levels higher than the toxicologically 
qualified amount could affect the safety and efficacy of the 
product (Savkare A. D, 2016). 
 
 
Figure 5: Schematic representation of Strategies for applying QbD for Impurity profiling (Palve R. et. al., 2018) 
Applications: (Venkata et.al., 2016). 
Drug Impurity   Method 
Amphotericin B Tetraenes HPLC with UV 
Atopine sulphate Apo atopine HPLC with UV 
Cloxacilin N,N, dimethylaniline   HPLC with GC 
Doxirubicine hydrochloride Acetone &Ethanol   HPLC with GC 
Dextrose 5-hydroxy methyl fulfural HPLC with UV 
Ethambytal Hydrochloride 2 amino butanol TLC 
Flurescene sodium Dimethyl formaamide HPLC with GC 
Farmyctin Sulphate Neamine TLC 
Marcptopurine Hypoxinthine HPLC with UV 
Metformin Cynoguanidine HPLC with UV 
Topiramate     Topiramate RC-A HPLC with RI 
Topiramate 
 
Sulpha mate HPLC with IC 
  Artemether Artemisinin TLC 
Hyoscine butyl bromide   Impurity G HPTLC 
Lansoprazole Sulfide Impurity   HPLC With (UV)                                
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Conclusion 
A high quality of drug substances and products helps to 
provide a consumer protection, hence the manufacturing 
companies focussed on isolation, separation, identification and 
characterization of impurities during the developmental 
stages. Identification of impurities establishes an overall profile 
of a drug and drug product which includes its toxicity and 
safety limits, limits of quantization and detection. Identification 
and isolation of impurities should start right from using API till 
the finished dosage form of a drug. There should be well 
established and standard specifications in the guidelines for 
overall control and isolation  of  impurities  which  should  
serve  as  a  guiding  specification  to  all  the  regulatory  
agencies pharmaceutical drugs substances and drugs products 
manufacturers. Validation of methods to identify and 
characterize impurities is a good approach and is currently 
being in practice for evaluation of impurities. The isolation, 
identification of impurities and impurity profiling is carried out 
using various techniques such as   chromatographic separation 
techniques generally used in combination with sophisticated 
instruments like HPLC, UPLC, GC, and SFC. Also some 
hyphenated techniques like LC-MS-MS, HPLC-DAD-MS, and 
HPLC-DAD-NMR-MS. These are very helpful and 
advantageous techniques for characterization of impurity 
profiling. To providing documentary evidence the quality by 
design approach is very effective and promising tool for 
reducing the trials. QbD provides or generate statistical data 
which is help full for further reference purpose. 
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